Frazier Lifesciences Acquisition Corporation
FLACU
NASDAQ Capital Market9.50
USD
+0.23
- -
CIK
0001828326
ISIN
KYG3710A1215
Return %
Stock
S&P500
1Y
-4.47
18.21
3Y
-7.59
63.29
5Y
-7.59
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Two Union Square Seattle WA United States of America 98101
- IPO Date
- Dec 9, 2020
- CIK
- 0001828326
- Similar Companies
- Business
- Frazier Lifesciences Acquisition Corporation Frazier Lifesciences Acquisition Corporation (FLACU) is a blank check special purpose acquisition company focused on effecting mergers, share exchanges, asset acquisitions, stock purchases, reorganizations or similar business combinations with one or more businesses or entities in the life sciences sector, including pharmaceuticals, biotechnology, medical devices and related healthcare services; the company holds proceeds from its initial public offering in a trust account and generates no current operating revenues. Sponsored by Frazier Healthcare Partners, a Seattle-based private equity firm with expertise in therapeutics, medical technology and specialty services, it targets opportunities across North America and select international markets, leveraging the sponsor's domain knowledge for due diligence and deal structuring. Incorporated in Delaware in October 2020 with offices in Seattle, Washington, the company raised $138 million in its December 2020 IPO and is led by executives from healthcare investing and corporate development backgrounds under an independent board. In a major development, it completed a business combination with NewAmsterdam Pharma Holding B.V. in November 2022, following shareholder approval and an oversubscribed $235 million PIPE financing led by Frazier Healthcare Partners and Bain Capital Life Sciences, resulting in the combined entity listing on Nasdaq under tickers NAMS and NAMSW with pro forma cash of at least $470 million to advance obicetrapib, a CETP inhibitor for cardiometabolic diseases. Post-merger, FLACU units continue trading on OTC markets as residual securities, reflecting the SPAC's lifecycle completion without further active operations or recent strategic shifts.